B-intervention	0	5	Novel
I-intervention	6	16	hyaluronan
I-intervention	17	28	formulation
O	29	32	for
O	33	43	preventing
B-condition	44	49	acute
I-condition	50	54	skin
I-condition	55	64	reactions
O	65	67	in
O	68	74	breast
O	75	81	during
O	82	94	radiotherapy
O	94	95	:
O	96	97	a
O	98	108	randomized
O	109	117	clinical
O	118	123	trial
O	123	124	.

O	125	127	We
O	128	137	conducted
O	138	139	a
O	140	150	randomized
O	150	151	,
O	152	158	double
O	158	159	-
O	159	164	blind
O	164	165	,
O	166	173	vehicle
O	173	174	-
O	174	184	controlled
O	185	193	clinical
O	194	199	trial
O	200	202	to
O	203	214	investigate
O	215	218	the
O	219	222	use
O	223	225	of
O	226	227	a
O	228	231	new
O	232	243	proprietary
O	244	254	hyaluronan
O	255	256	(
O	256	258	HA
O	258	259	)
O	260	271	formulation
O	272	275	for
O	276	279	the
O	280	290	prevention
O	291	293	of
O	294	299	acute
O	300	304	skin
O	305	313	toxicity
O	314	316	in
O	317	323	breast
O	324	330	cancer
O	331	339	patients
O	340	350	undergoing
O	351	363	radiotherapy
O	364	365	(
O	365	367	RT
O	367	368	)
O	368	369	.

B-total-participants	370	376	Thirty
B-eligibility	377	382	women
I-eligibility	383	387	with
I-eligibility	388	394	breast
I-eligibility	395	401	cancer
I-eligibility	402	412	undergoing
I-eligibility	413	418	whole
I-eligibility	419	425	breast
I-eligibility	426	428	RT
O	429	433	were
O	434	442	enrolled
O	442	443	.

O	444	448	Each
O	449	456	patient
O	457	460	was
O	461	469	randomly
O	470	478	assigned
O	479	481	to
O	482	484	HA
O	485	496	formulation
O	497	498	(
O	498	503	study
O	504	509	cream
O	509	510	,
O	511	512	S
O	512	513	)
O	514	516	on
O	517	520	the
O	521	527	medial
O	528	530	or
O	531	538	lateral
O	539	543	half
O	544	546	of
O	547	550	the
O	551	561	irradiated
O	562	568	breast
O	569	572	and
O	573	576	the
B-control	577	584	control
I-control	585	590	cream
I-control	591	592	(
I-control	592	599	placebo
I-control	599	600	,
I-control	601	602	P
I-control	602	603	)
O	604	606	on
O	607	610	the
O	611	616	other
O	617	621	half
O	621	622	.

O	623	626	The
O	627	634	primary
O	635	643	endpoint
O	644	647	was
B-outcome-Measure	648	657	physician
I-outcome-Measure	657	658	'
I-outcome-Measure	658	659	s
I-outcome-Measure	660	670	evaluation
I-outcome-Measure	671	673	of
I-outcome-Measure	674	678	skin
I-outcome-Measure	679	687	symptoms
O	688	690	at
O	691	695	week
O	696	697	5
O	698	704	during
O	705	707	RT
O	708	711	and
O	712	716	week
O	717	718	2
O	719	723	post
O	723	724	-
O	724	726	RT
O	726	727	.

O	728	730	We
O	731	735	also
O	736	745	collected
O	746	754	patients
O	754	755	'
O	756	767	independent
O	768	778	assessment
O	779	781	of
O	782	786	skin
O	787	792	after
O	793	795	RT
O	795	796	,
O	797	804	patient
O	804	805	'
O	805	806	s
O	807	814	product
O	815	825	preference
O	825	826	,
O	827	830	and
O	831	833	an
O	834	845	independent
O	846	855	physician
O	856	861	panel
O	862	872	assessment
O	873	875	of
O	876	880	skin
O	881	890	reactions
O	891	896	based
O	897	899	on
O	900	911	photographs
O	911	912	.

B-total-participants	913	919	Twenty
I-total-participants	919	920	-
I-total-participants	920	925	eight
O	926	934	patients
O	935	939	were
O	940	949	evaluable
O	949	950	.

O	951	953	On
O	954	963	physician
O	963	964	'
O	964	965	s
O	966	976	evaluation
O	976	977	,
O	978	983	there
O	984	987	was
O	988	990	no
O	991	1002	significant
O	1003	1013	difference
O	1014	1016	in
B-outcome	1017	1026	radiation
I-outcome	1027	1037	dermatitis
O	1038	1045	between
O	1046	1047	S
O	1048	1051	and
O	1052	1053	P
O	1054	1057	and
O	1058	1060	no
O	1061	1068	overall
O	1069	1079	preference
O	1080	1082	to
O	1083	1089	either
O	1090	1095	cream
O	1096	1098	at
O	1099	1103	week
O	1104	1105	5
O	1106	1112	during
O	1113	1115	or
O	1116	1120	week
O	1121	1122	2
O	1123	1127	post
O	1127	1128	-
O	1128	1130	RT
O	1130	1131	.

O	1132	1136	More
O	1137	1145	patients
O	1146	1155	preferred
O	1156	1157	S
O	1158	1160	in
O	1161	1171	evaluating
B-outcome	1172	1176	skin
I-outcome	1177	1187	appearance
I-outcome	1188	1191	and
I-outcome	1192	1196	skin
I-outcome	1197	1206	reactions
O	1206	1207	,
O	1208	1211	but
O	1212	1216	this
O	1217	1220	did
O	1221	1224	not
O	1225	1230	reach
O	1231	1242	statistical
O	1243	1255	significance
O	1255	1256	.

O	1257	1267	Univariate
O	1268	1276	analysis
O	1277	1283	showed
O	1284	1288	that
O	1289	1299	physicians
O	1300	1303	had
O	1304	1306	an
O	1307	1314	overall
O	1315	1325	preference
O	1326	1328	to
O	1329	1332	the
O	1333	1334	S
O	1335	1340	cream
O	1341	1343	at
O	1344	1348	week
O	1349	1350	2
O	1351	1355	post
O	1355	1356	-
O	1356	1358	RT
O	1359	1361	in
O	1362	1370	patients
O	1371	1375	with
O	1376	1382	larger
O	1383	1390	breasts
O	1390	1391	.

O	1392	1394	On
O	1395	1398	the
O	1399	1410	independent
O	1411	1416	panel
O	1417	1427	assessment
O	1427	1428	,
O	1429	1430	3
O	1431	1440	reviewers
O	1441	1444	saw
O	1445	1447	no
O	1448	1459	significant
O	1460	1470	difference
O	1471	1473	in
O	1474	1483	radiation
O	1484	1492	toxicity
O	1492	1493	,
O	1494	1501	whereas
O	1502	1505	one
O	1506	1514	reviewer
O	1515	1523	reported
O	1524	1530	better
O	1531	1535	skin
O	1536	1543	outcome
O	1544	1548	with
O	1549	1550	S
O	1551	1556	cream
O	1557	1559	at
O	1560	1564	week
O	1565	1566	5
O	1566	1567	.

O	1568	1570	We
O	1571	1576	found
O	1577	1578	a
O	1579	1595	nonstatistically
O	1596	1607	significant
O	1608	1615	patient
O	1616	1626	preference
O	1627	1630	but
O	1631	1638	overall
O	1639	1641	no
O	1642	1653	significant
O	1654	1669	radioprotective
O	1670	1677	effects
O	1678	1681	for
O	1682	1686	this
O	1687	1689	HA
O	1690	1701	formulation
O	1702	1710	compared
O	1711	1715	with
O	1716	1723	placebo
O	1724	1730	except
O	1731	1733	in
O	1734	1742	patients
O	1743	1747	with
O	1748	1754	larger
O	1755	1762	breasts
O	1762	1763	.

O	1764	1767	The
O	1768	1773	study
O	1774	1777	was
O	1778	1788	registered
O	1789	1791	at
O	1792	1795	www
O	1795	1796	.
O	1796	1810	clinicaltrials
O	1810	1811	.
O	1811	1814	gov
O	1815	1816	(
O	1816	1827	NCT02165605
O	1827	1828	)
O	1828	1829	.
